Abiopharma

🔍 Zanotti Katherine S (Executive)

Company: EXACT SCIENCES CORP (EXAS)

Report Date: 2026-03-23

Detailed Transactions and Holdings:

• Sold 55,361 shares of Common Stock (Direct)
  Date: 2026-03-23 | Code: D | equity_swap_involved: false | shares_owned_after: 5,398.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,398 shares of Common Stock (Direct)
  Date: 2026-03-23 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").
• F2: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.